Samuel D. Rabkin

14.6k total citations · 3 hit papers
170 papers, 11.1k citations indexed

About

Samuel D. Rabkin is a scholar working on Genetics, Epidemiology and Molecular Biology. According to data from OpenAlex, Samuel D. Rabkin has authored 170 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Genetics, 87 papers in Epidemiology and 85 papers in Molecular Biology. Recurrent topics in Samuel D. Rabkin's work include Virus-based gene therapy research (127 papers), Herpesvirus Infections and Treatments (84 papers) and CAR-T cell therapy research (44 papers). Samuel D. Rabkin is often cited by papers focused on Virus-based gene therapy research (127 papers), Herpesvirus Infections and Treatments (84 papers) and CAR-T cell therapy research (44 papers). Samuel D. Rabkin collaborates with scholars based in United States, China and Japan. Samuel D. Rabkin's co-authors include Robert L. Martuza, Tomoki Todo, Dipongkor Saha, William D. Hunter, Hiroaki Wakimoto, R L Martuza, Toshihiro Mineta, Takahito Yazaki, Masahiro Toda and E. Antonio Chiocca and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Samuel D. Rabkin

170 papers receiving 10.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

2000 794 citations Samuel D. Rabkin, Tomoki Todo et al. profile →
Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1995 696 citations Samuel D. Rabkin, Robert L. Martuza et al. profile →
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade

2017 445 citations Dipongkor Saha, Robert L. Martuza et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Samuel D. Rabkin United States	55	7.3k	5.4k	4.9k	3.4k	1.4k	170	11.1k
Michel Perricaudet France	64	6.7k 0.9×	7.9k 1.5×	3.1k 0.6×	1.5k 0.5×	1.8k 1.3×	173	13.4k
Tomoki Todo Japan	43	3.4k 0.5×	3.1k 0.6×	2.8k 0.6×	1.8k 0.5×	746 0.5×	143	7.2k
Rob C. Hoeben Netherlands	48	3.8k 0.5×	4.0k 0.7×	1.7k 0.3×	802 0.2×	1.3k 0.9×	208	7.6k
Izumu Saito Japan	47	2.5k 0.3×	4.7k 0.9×	1.2k 0.2×	2.3k 0.7×	869 0.6×	155	8.9k
Manfred Gossen Germany	37	4.2k 0.6×	9.5k 1.8×	2.5k 0.5×	588 0.2×	1.1k 0.8×	90	12.5k
Federico Mingozzi United States	49	6.9k 0.9×	7.1k 1.3×	2.6k 0.5×	994 0.3×	614 0.4×	122	10.3k
H. Earl Ruley United States	40	2.4k 0.3×	6.3k 1.2×	4.5k 0.9×	437 0.1×	998 0.7×	74	10.1k
Stefan Kochanek Germany	47	5.1k 0.7×	5.7k 1.1×	1.5k 0.3×	612 0.2×	671 0.5×	150	7.9k
Ulrike Blömer Germany	20	4.6k 0.6×	5.6k 1.0×	929 0.2×	946 0.3×	764 0.5×	34	8.2k
Susan M. Kingsman United Kingdom	54	2.6k 0.4×	6.5k 1.2×	594 0.1×	863 0.3×	984 0.7×	155	9.5k

Countries citing papers authored by Samuel D. Rabkin

Since Specialization

Citations

This map shows the geographic impact of Samuel D. Rabkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel D. Rabkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel D. Rabkin more than expected).

Fields of papers citing papers by Samuel D. Rabkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel D. Rabkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel D. Rabkin. The network helps show where Samuel D. Rabkin may publish in the future.

Co-authorship network of co-authors of Samuel D. Rabkin

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel D. Rabkin. A scholar is included among the top collaborators of Samuel D. Rabkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel D. Rabkin. Samuel D. Rabkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hudson, M’Liss A., Robert H. Newman, Checo J. Rorie, et al.. (2025). Promoting the therapeutic potential of interleukin-7 (IL-7) by expression in viral vectors. Cancer Gene Therapy. 32(11). 1166–1176. 2 indexed citations

Borlongan, Mia C., et al.. (2024). Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?. Journal for ImmunoTherapy of Cancer. 12(5). e008025–e008025. 13 indexed citations

Hua, Lingyang, Alessandra Gurtner, Juri Kiyokawa, et al.. (2022). Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma. Biomedicine & Pharmacotherapy. 155. 113843–113843. 10 indexed citations

Kiyokawa, Juri, Shanawaz M. Ghouse, Jordi Martínez‐Quintanilla, et al.. (2020). Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clinical Cancer Research. 27(3). 889–902. 77 indexed citations

Li, Ming, Guoping Li, Juri Kiyokawa, et al.. (2020). Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathologica Communications. 8(1). 221–221. 37 indexed citations

Bommareddy, Praveen K., Andrew Zloza, Samuel D. Rabkin, & Howard L. Kaufman. (2019). Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. OncoImmunology. 8(7). e1591875–e1591875. 97 indexed citations

Bommareddy, Praveen K., Samuel D. Rabkin, & Howard L. Kaufman. (2019). Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. OncoImmunology. 8(4). e1571390–e1571390. 1 indexed citations

Wu, Ming-Ru, Lior Nissim, Doron Stupp, et al.. (2019). A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS). Nature Communications. 10(1). 2880–2880. 51 indexed citations

Stanciu, Monica, Joshua Gorham, Hiroko Wakimoto, et al.. (2019). Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. Nature Communications. 10(1). 2910–2910. 83 indexed citations

10.

Saha, Dipongkor, et al.. (2018). Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models. Clinical Cancer Research. 24(14). 3409–3422. 59 indexed citations

11.

Esaki, Shinichi, Fares Nigim, Juri Kiyokawa, et al.. (2017). Blockade of transforming growth factor‐β signaling enhances oncolytic herpes simplex virus efficacy in patient‐derived recurrent glioblastoma models. International Journal of Cancer. 141(11). 2348–2358. 37 indexed citations

12.

Rheinbay, Esther, Mario L. Suvà, Shawn Gillespie, et al.. (2013). An Aberrant Transcription Factor Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma. Cell Reports. 3(5). 1567–1579. 197 indexed citations

13.

Kleijn, Anne, John W. Chen, Jason S. Buhrman, et al.. (2011). Distinguishing Inflammation from Tumor and Peritumoral Edema by Myeloperoxidase Magnetic Resonance Imaging. Clinical Cancer Research. 17(13). 4484–4493. 29 indexed citations

14.

Cheema, Tooba A., Ryuichi Kanai, Hiroaki Wakimoto, et al.. (2011). Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts. Clinical Cancer Research. 17(23). 7383–7393. 70 indexed citations

15.

Kanai, Ryuichi, Hiroaki Wakimoto, Robert L. Martuza, & Samuel D. Rabkin. (2011). A Novel Oncolytic Herpes Simplex Virus that Synergizes with Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma Stem Cells. Clinical Cancer Research. 17(11). 3686–3696. 68 indexed citations

16.

Passer, Brent J., Tooba A. Cheema, Bingsen Zhou, et al.. (2010). Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication. Cancer Research. 70(10). 3890–3895. 26 indexed citations

17.

Wakimoto, Hiroaki, Santosh Kesari, Christopher J. Farrell, et al.. (2009). Human Glioblastoma–Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors. Cancer Research. 69(8). 3472–3481. 279 indexed citations

18.

Kuroda, Toshihiko, Samuel D. Rabkin, & Robert L. Martuza. (2006). Effective Treatment of Tumors with Strong β-Catenin/T-Cell Factor Activity by Transcriptionally Targeted Oncolytic Herpes Simplex Virus Vector. Cancer Research. 66(20). 10127–10135. 36 indexed citations

19.

Fukuhara, Hiroshi, Robert L. Martuza, Samuel D. Rabkin, Yoshikazu Ito, & Tomoki Todo. (2005). Oncolytic Herpes Simplex Virus Vector G47Δ in Combination with Androgen Ablation for the Treatment of Human Prostate Adenocarcinoma. Clinical Cancer Research. 11(21). 7886–7890. 56 indexed citations

20.

Todo, Tomoki, et al.. (1999). Replication-Competent Herpes Simplex Virus Vector G207 and Cisplatin Combination Therapy for Head and Neck Squamous Cell Carcinoma. Neoplasia. 1(2). 162–169. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact